Monte Rosa Therapeutics Shares Surge on Major Novartis Partnership Expansion
Published on 09/18/2025 at 15:27 | Redaktion boerse-global.deA landmark expansion of Monte Rosa Therapeutics’ existing collaboration with pharmaceutical leader Novartis has ignited a dramatic surge in its stock value. The strategic alliance, which could ultimately be valued at up to $5.7 billion, focuses on pioneering novel Molecular Glue Degrader therapies designed to treat a range of immune disorders.
The financial markets reacted with immediate and forceful optimism to the announcement. In pre-market trading on Monday, Monte Rosa Therapeutics’ equity skyrocketed by as much as 61 percent to reach $7.74 per share. Although the gains moderated slightly as the session progressed, the stock still closed the official trading day with a formidable 44 percent advance, settling at $6.93. This powerful investor response underscores the market’s strong endorsement of the deal’s strategic significance.
This... Read more...
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
